Curated News
By: NewsRamp Editorial Staff
June 10, 2026

Voyageur Submits Permit for Barite Bulk Sampling at Frances Creek

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Voyageur Pharmaceuticals' MYAB permit submission de-risks its Frances Creek barite project, targeting high-margin pharmaceutical barium with 75% gross margins.
  • The MYAB application covers a five-year, low-impact exploration program with dry processing, geotechnical drilling, and progressive reclamation to advance the feasibility study.
  • Voyageur aims to secure North American supply of pharmaceutical barium contrast agents, potentially lowering costs and improving imaging quality for patients.
  • The Frances Creek barite averages 98.8% BaSO4, exceeding pharmaceutical grade, and will be tested for use in FDA-approved contrast agents.

Impact - Why it Matters

This news matters because it advances Voyageur's plan to become a domestic supplier of pharmaceutical-grade barium contrast agents, reducing reliance on imported synthetic products. The successful extraction and validation of high-purity barite could lead to lower-cost, higher-quality imaging agents, benefiting healthcare systems and patients. Moreover, the project's vertical integration model may stabilize supply chains and create economic opportunities in Canada.

Summary

Voyageur Pharmaceuticals Ltd. (TSX-V: VM) has taken a significant step forward in its Frances Creek barite project by submitting a Multi-Year Area-Based (MYAB) Notice of Work application to the British Columbia Ministry of Mining and Critical Minerals. The application seeks approval for a five-year advanced exploration program on a 76.8-hectare area, including exploration trenching, access trail development, and construction of a processing area and mine rock storage facility, all on previously disturbed forestry land. The proposed Year 1 program includes the extraction of 2,000 tonnes of high-grade barite ore (specific gravity 4.5) from the A and B zones, which will be processed on site using dry densimetric technology to produce an initial concentrate. This concentrate will be shipped to Voyageur's future facility for testing and validation of its proprietary process to meet US Pharmacopeia (USP) specifications for pharmaceutical-grade barium contrast agents. The MYAB framework allows for further exploration sampling in subsequent years, up to 1,000 tonnes per cell per year. Additionally, the application includes a geotechnical drilling program to provide data for quarry pit wall designs and waste rock storage configurations, which is essential for completing an NI 43-101 Final Feasibility Study. Brent Willis, CEO, emphasized that this submission is a de-risking milestone that supports process development and validation, positioning Voyageur as a potential secure North American supplier of pharmaceutical barium contrast products. The project hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with recent tests confirming purity exceeding 97.5% (average 98.8% BaSO4), as detailed in a March 3, 2026 news release. The Preliminary Economic Assessment (PEA) outlines a low-cost open-pit development with a 10-year horizon, $36 million capital over three years, and an 11-month payback period after production starts, with average operating gross margins of ~75%. Voyageur's strategy is to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw materials to final production, embodying its motto "From the Earth to the Bottle."

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Voyageur Submits Permit for Barite Bulk Sampling at Frances Creek

blockchain registration record for this content.